Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 19, 2025

SELL
$80.97 - $117.93 $809,700 - $1.18 Million
-10,000 Reduced 90.91%
1,000 $81,000
Q4 2024

Feb 14, 2025

BUY
$80.97 - $117.93 $890,670 - $1.3 Million
11,000 New
11,000 $900,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $1.97B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Toronto Dominion Bank Portfolio

Follow Toronto Dominion Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

News

Stay updated on Toronto Dominion Bank with notifications on news.